RiaSTAP is a purified fibrinogen concentrate indicated for the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.    From Wordnik.com.  [BioSpace.com Featured News and Stories] Reference

Food and Drug Administration (FDA) has granted marketing approval for RiaSTAP, the first and only treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.    From Wordnik.com.  [Emaxhealth] Reference

Food and Drug Administration (FDA) has granted marketing approval for RiaSTAP (TM), the first and only treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.    From Wordnik.com.  [BioSpace.com Featured News and Stories] Reference

Homer VM, George PM, Brennan SO (2009) A deep intronic mutation in FGB creates a consensus exonic splicing enhancer motif that results in afibrinogenemia caused by aberrant mRNA splicing, which can be corrected in vitro with antisense oligonucleotide treatment.    From Wordnik.com.  [PLoS ONE Alerts: New Articles] Reference